New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:40 EDTEXELSummer Street's chief scientific officer holds analyst/industry conference call
Chief Science Officer Classen discusses Exelixis' Cabozantinib for treatment of mestastatic prostate cancer on an Analyst/Industry conference call to be held on March 20 at 10 am.
News For EXEL From The Last 14 Days
Check below for free stories on EXEL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:34 EDTEXELExelixis reports Q2 EPS (38c), consensus (39c)
Reports Q2 revenue $6.6M, consensus $5.66M.
July 29, 2014
05:58 EDTEXELExelixis shares rallied on Roche rumors, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use